

Note: This document is a translation of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.

## Press Release



### Notice of Revisions to the Forecast of Consolidated Financial Results for FY2025

**TOKYO, November 4, 2025** - ASKA Pharmaceutical Holdings Co., Ltd. (TSE:4886, Head Office: Minato-ku, Tokyo) has resolved at the Board of Directors meeting held today to revise the full-year consolidated performance forecasts for FY2025 announced on May 12, 2025 as follows.

#### 1. Revisions to the Forecast of Consolidated Financial Results

##### (1) Forecast of Consolidated Financial Results for FY2025 (April 1, 2025 to March 31, 2026)

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of parent	Earnings per share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Previous forecast (A)	75,000	6,800	6,800	5,200	183.44
Revised forecast (B)	71,000	6,000	6,000	5,000	176.22
Change (B-A)	(4,000)	(800)	(800)	(200)	
Rate of change (%)	(5.3%)	(11.8%)	(11.8%)	(3.8%)	
(Reference) Results for the previous FY2024	64,139	5,331	5,107	5,101	179.95

##### (2) Reason for the Revisions

Regarding the sales transactions of imported products procured from outside Vietnam and sold domestically by the Company's Vietnamese subsidiary, Ha Tay Pharmaceutical Joint Stock Company (hereinafter, "Hataphar"), the consolidated statement of income for the first quarter of FY2025 recorded the total amount as net sales. However, after reviewing the above transaction, the Company determined that Hataphar does not control the goods or services to be transferred to the customer and that the transaction falls under the category of an "agent" that provides only the service of arranging these goods or services.

In accordance with the Group's accounting policies, the Company has therefore decided to amend its sales recording method to a net basis, whereby the amount paid to suppliers is deducted from the amount received from customers. Consequently, the forecasted net sales have been revised downward from the previously announced figure.

With regard to profits, the Company has revised its forecasts for operating profit ordinary income, and net income attributable to owners of parent to be lower than previously announced due to various factors such as an expected increase in R&D expenses resulting from the active promotion of R&D investments aimed at expanding the pipeline for future growth and strengthening drug discovery capabilities.

There will be no change to dividends in line with the forecast revision. The Company's policy is to maintain stable dividends while returning profits in line with business performance.

(NOTE) The above forecasts have been prepared based on information available as of the announcement date and are subject to various uncertainties. As a result, actual results may differ from this forecast.

---

**Media Contacts**

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: [kouhou@aska-pharma.co.jp](mailto:kouhou@aska-pharma.co.jp)